Skip to main content
Figure 4 | Journal of Experimental & Clinical Cancer Research

Figure 4

From: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models

Figure 4

AZD8931 inhibits the growth of SUM149 and FC-IBC-02 cells in vivo in SCID mice. SUM149 (A) and FC-IBC-02 (C) cells were orthotopically transplanted into the mammary fat pads of SCID mice. Animals were randomized into groups (n = 5/group) when tumor volumes were approximately 50–80 mm3. AZD8931 was given by oral gavage at doses of 25 mg/kg per day, 5 days/week for 4 weeks. Paclitaxel was given twice weekly by subcutaneously injection at 10 mg/kg for 4 weeks. The mean tumor volumes were measured at the time points indicated. In SUM149 xenografts (A), *P < 0.01 (vs. control), **P = 0.01 (vs. paclitaxel + AZD8931). In FC-IBC-02 xenografts (C), *P < 0.001 (vs. control), **P < 0.01 (vs. paclitaxel + AZD8931). SUM149 (B) and FC-IBC-02 (D), the size of tumors was measured by weights (mg) after tumors were removed from mice at the end of experiments. The data shown represent the mean of tumor weights with SD. *P < 0.05 (vs. control); **P < 0.01 compared to control. The combination of paclitaxel + AZD8931 compared with paclitaxel (P = 0.008, SUM149; P = 0.001, FC-IBC-02).

Back to article page